CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 7, 2025
- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) -
Read more at globenewswire.com3.37
+0.04 (+1.2%)
Find more stocks in the Stock Screener
CTMX Latest News and Analysis
